KalVista Pharmaceuticals, Inc.
KALVNASDAQHealthcare● Active
$26.99
+$0.04(+0.13%)
Market Cap$1.4B
P/E Ratio—
52W High$26.99
52W Low$9.83
KalVista Pharmaceuticals, Inc.（KALV）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · KALV · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2025-04 | 2024-04 | 2023-04 | 2022-04 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $73.62M | $0.00M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $6.08M | $0.00M | $86.17M | $0.00M | $0.00M |
| Gross Profit | $67.54M | $0.00M | ($86.17M) | $0.00M | $0.00M |
| Gross Margin %(computed) | 91.75% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $55.64M | $71.71M | $86.17M | $80.28M | $70.17M |
| G&A Expenses | $0.00M | $116.29M | $54.28M | $30.59M | $26.45M |
| Total Operating Expenses | $239.38M | $188.00M | $54.28M | $110.87M | $96.61M |
| Operating Income | ($171.84M) | ($188.00M) | ($140.44M) | ($110.87M) | ($96.61M) |
| Operating Margin %(computed) | -233.42% | — | — | — | — |
| Interest Income | $8.68M | $6.43M | $3.90M | $2.23M | $1.09M |
| Interest Expense | $19.34M | $5.79M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($171.42M) | ($180.05M) | ($135.10M) | ($92.91M) | ($82.34M) |
| Income Tax Expense | ($7.13M) | $3.39M | ($8.45M) | $0.00M | $0.00M |
| Net Income | ($164.29M) | ($183.44M) | ($126.64M) | ($92.91M) | ($82.34M) |
| Net Margin %(computed) | -223.16% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.23 | $-3.69 | $-3.44 | $-3.33 | $-3.36 |
| Wtd Avg Shares | 50.90M | 49.65M | 36.79M | 27.89M | 24.47M |
| EBITDA | ($170.38M) | ($173.33M) | ($134.28M) | ($94.37M) | ($80.75M) |
| EBITDA Margin %(computed) | -231.45% | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · M
深入了解KalVista Pharmaceuticals, Inc.
关于KalVista Pharmaceuticals, Inc.（KALV）损益表
KalVista Pharmaceuticals, Inc.（KALV）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，KALV实现营收$0.07B，毛利润$0.07B（毛利率91.75%），净利润($0.16B)（净利率-223.16%）。
常见问题
KALV · 4 问KalVista Pharmaceuticals, Inc.（KALV）2025财年营收为$0.07B，同比up—%。
KALV revenueKALV salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08